For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping GEOMETRY mono-1
Thoracic Malignancies
Non-small-cell Lung Cancer
METex14 skipping
GEOMETRY mono-1
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
SCORE
F3
3
Atezolizumab
-
Platinum-based chemotherapy
First-line treatment of patients with high PD-L1 expression ≥50% TC or ≥10% IC and who do not have EGFR mutant or ALK-positive NSCLCIMpower110
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 expression ≥50% TC or ≥10% IC
IMpower110
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
5
Pembrolizumab
ChT
Placebo plus ChT
Treatment of locally recurrent unresectable or metastaticTNBC in adults whose tumours express PD-L1 with a CPS ≥ 10 and who have not received prior chemotherapy KEYNOTE-355
Breast Cancer
Breast Cancer
Triple-negative, PD-L1 (CPS ≥10)
KEYNOTE-355
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
4
Nivolumab
-
Single arm
Treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapyCheckMate 275
Genitourinary Cancers
Urothelial Carcinoma
-
CheckMate 275
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
SCORE
F3
3
Osimertinib
-
Placebo
Adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutationsADAURA
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR exon 19 deletions or exon 21 (L858R) mutation
ADAURA
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
SCORE
F1
A
Margetuximab
ChT
Trastuzumab plus ChT
Treatment of adult patients who have received two or more prior anti-HER2 regimes, at least one of which was for metastatic diseaseSOPHIA
Breast Cancer
Breast Cancer
HER2+
SOPHIA
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
2
Trastuzumab deruxtecan
-
ChT (irinitecan or paclitaxel)
Treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma in patients who have received a prior trastuzumab-based regimenDESTINY-Gastric01
Gastrointestinal Cancers
Gastric or gastroesophageal junction adenocarcinoma
HER2+
DESTINY-Gastric01
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
4
Trabectedin
-
Dacarbazine
Treatment for patients with advanced soft-issue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients
Sarcoma
Soft tissue - Liposarcoma or leiomyosarcoma
-
-
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
2
Niraparib
-
Placebo
Maintenance treatment for patients with advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based ChT PRIMA/ENGOT-OV26/COG-3012
Gynaecological Malignancies
Ovarian, fallopian tubes and peritoneum cancer
HRD+
PRIMA/ENGOT-OV26/COG-3012
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
3
Olaparib
Bevacizumab
Placebo + bevacizumab
Maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instabilityPAOLA-1
Gynaecological Malignancies
High-grade epithelial ovarian, fallopian tube or primary peritoneal cancer
BRCA-mut
PAOLA-1
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
4
Olaparib
Bevacizumab
Placebo + bevacizumab
Maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instabilityPAOLA-1
Gynaecological Malignancies
High-grade epithelial ovarian, fallopian tube or primary peritoneal cancer
HRD+, BRCA-WT
PAOLA-1
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
2
Avelumab
-
Single arm
Adult patients with metastatic Merkel cell carcinoma (MCC)JAVELIN Merkel 200 (Part A - pretreated patients)
Skin Cancers
Merkel cell carcinoma
-
JAVELIN Merkel 200 (Part A - pretreated patients)
4
PRELIMINARY SCORE
ORR
ADJUSTMENTS
SCORE
F3
4
Nivolumab + ipilimumab
-
ChT with cisplatin or carboplatin plus pemetrexed
First-line treatment of adult patients with unresectable malignant pleural mesothelioma.CheckMate743
Thoracic Malignancies
Pleural mesothelioma
-
CheckMate743
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
3
Nivolumab + ipilimumab
-
Single arm
Patients with HCC who have been previously treated with sorafenibCheckMate 040
Gastrointestinal Cancers
Hepatobiliary Cancers - Hepatocellular Carcinoma
-
CheckMate 040
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
SCORE
F3
3
Tazemetostat
-
Single arm (Phase II)
Treatment for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resectionEZH-202
Sarcoma
Epithelioid
INI1-negative
EZH-202
1
PRELIMINARY SCORE
ORR
ADJUSTMENTS
SCORE
F3
1
Tepotinib
-
Single arm
For adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.VISION
Thoracic Malignancies
Non-small-cell Lung Cancer
METex14 skipping
VISION
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
SCORE
F3
3
Cemiplimab
-
Platinum based ChT (Crossover allowed)
First-line locally advanced NSCLC who are not candidates for definitive chemoradiation or metastatic NSCLCEMPOWER-Lung 1
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1>50% negative EGFR, ALK or ROS1
EMPOWER-Lung 1
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
4
Cabozantinib
-
Sunitinib
First-line treatment of adult patients with intermediate or poor risk advanced RCCCABOSUN
Genitourinary Cancers
Renal cell cancer
-
CABOSUN
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
3
Dostarlimab
-
Single arm
EMA: As monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.. FDA: Treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. GARNET
Gynaecological Malignancies
Endometrial Cancer
dMMR or MSI-H
GARNET
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
SCORE
F3
3
Nivolumab + ipilimumab
2 cycles of platinum-based ChT
Chemotherapy
First line treatment of mNSCLC with no sensitising EGFR mutation or ALK translocation CheckMate-9LA
Thoracic Malignancies
Non-small-cell Lung Cancer
-
CheckMate-9LA
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
4
5-FU/LV (fluorouracil + leucovorin)
-
Lomustine (MeCCNU) + vincristine + 5-FU
Patients with Dukes' stage B and C colon cancerNSABP C-03
Gastrointestinal Cancers
Colon Cancer
-
NSABP C-03
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
SCORE
F1
A
5-FU (fluorouracil)
Folinic acid
Observation
Patients with surgically resected colon cancer in Dukes' stage C
Gastrointestinal Cancers
Colon Cancer
-
-
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
SCORE
F1
A
5-FU/LV (fluorouracil + leucovorin)
-
Observation
High-risk stage II or stage III colon cancerNCCTG 874651
Gastrointestinal Cancers
Colon Cancer
-
NCCTG 874651
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
SCORE
F1
A
5-FU (fluorouracil)
Folinic acid
Surgery alone
Patients with resectable Dukes B and C (AJCC/UICC Stage II and Stage III) colon carcinomaGIVIO-SITAC 01
Gastrointestinal Cancers
Colon Cancer
-
GIVIO-SITAC 01
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
SCORE
F1
A
5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole)
-
Surgery alone (Meta-analysis)
Patients with stage II and III colon cancer (ITT and age stratified including >70 years)
Gastrointestinal Cancers
Colon Cancer
-
-
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
SCORE
F1
A
5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole)
-
Surgery alone (Pooled-analysis)
Patients with stage II and III colon cancer
Gastrointestinal Cancers
Colon Cancer
-
-
A
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F1
A
5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole)
-
Surgery alone (Meta-analysis)
Patients with resected stage II and III colon cancer
Gastrointestinal Cancers
Colon Cancer
-
-
A
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F1
A
5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole)
-
Surgery alone (Meta-analysis)
Patients with resected stage II and III colon cancer
Gastrointestinal Cancers
Colon Cancer
-
-
A
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F1
A
5FU/LEV (5-fluorouracil + levamisole)
-
Levamisole
Resected stage III (Dukes stage C) colon cancerIntergroup 0035
Gastrointestinal Cancers
Colon Cancer
-
Intergroup 0035
A
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F1
A
Tivozanib
-
Sorafenib
Adult patients with relapsed or refractory advanced RCC following ≥2 prior systemic therapies TIVO-3
Genitourinary Cancers
Renal cell cancer
-
TIVO-3
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
3
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.